Samir D. Undevia

Samir D. Undevia

Hematology | Oncology
177 E. Brush Hill Rd.
Cancer Center
Elmhurst, IL 60126

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Radical en bloc resection of thoracic outlet sarcoma with fibula free flap and neurovascular reconstruction.

Radical en bloc resection of thoracic outlet sarcoma with fibula free flap and neurovascular reconstruction.

Journal: JTCVS techniques
Published: April 24, 2026

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.

Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma.

Journal: Cancer
Published: June 21, 2019

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)
Published: May 28, 2019

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 07, 2019

An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population.

An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population.

Journal: Journal of racial and ethnic health disparities
Published: June 02, 2015

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors.

Journal: Investigational new drugs
Published: April 13, 2015

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 17, 2014

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 25, 2014

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

Journal: Pharmacogenetics and genomics
Published: December 05, 2013

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.

Journal: The Lancet. Oncology
Published: March 13, 2013

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 09, 2012

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)
Published: April 15, 2008
Showing 1-12 of 12

Last Updated: 09/26/2026